Skip Navigation


Carcinogenesis Advance Access first published online on July 19, 2006
This version published online on August 9, 2006
Carcinogenesis, doi:10.1093/carcin/bgl069
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrowOA All Versions of this Article:
27/12/2434    most recent
bgl069v2
bgl069v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Chen, X.-c.
Right arrow Articles by Li, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, X.-c.
Right arrow Articles by Li, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 The Author(s)
Received October 4, 2005
Revised March 4, 2006
Accepted April 21, 2006

MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION

Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs

Xian-cheng Chen 1 {dagger}, Rui Wang 2 {dagger}, Xia Zhao 3, Yu-quan Wei 2 *, Min Hu 2, Yang-sheng Wang 2, Xiao-wei Zhang 2, Ru Zhang 2, Lin Zhang 2, Bin Yao 2, Lian Wang 2, Yong-qian Jia 2, Ting-ting Zeng 2, Jin-liang Yang 2, Ling Tian 2, Bing Kan 2, Xiao-juan Lin 3, Song Lei 2, Hong-xin Deng 2, Yan-jun Wen 2, Yong-qiu Mao 2, and Jiong Li 2

1 National Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Guo Xue Xian No. 37, Chengdu, Sichuan 610041, People's Republic of China; Department of Gynecology and Obstetrics, Second West China Hospital, West China Medical School, Sichuan University, Guo Xue Xian No. 37, Chengdu, Sichuan 610041, People's Republic of China
2 National Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Guo Xue Xian No. 37, Chengdu, Sichuan 610041, People's Republic of China
3 Department of Gynecology and Obstetrics, Second West China Hospital, West China Medical School, Sichuan University, Guo Xue Xian No. 37, Chengdu, Sichuan 610041, People's Republic of China

* To whom correspondence should be addressed.
Yu-quan Wei, E-mail: yuquawei{at}vip.sina.com


  Abstract

Mesenchymal stem cells (MSCs) were adenovirally engineered to secrete interleukin-12 (AdIL-12-MSCs) and evaluated for their anticarcinogenesis efficacy against three kinds of unestablished tumor models including B16 melanoma, LLC Lewis lung cancer and HCC hepatoma. Injection of AdIL-12-MSCs into protected mice before tumor inoculation prevented all of 12 mice in B16 preventive groups, 10 out of 12 in LLC lung cancer model and 11 out of 12 mice in HCC hepatoma model from developing tumors, whereas the control groups pre-receiving PBS were validated for 100% carcinogenesis; the tumor formation rates in free-AdIL-12 and vacant MSC groups were unveiled between ~83 and 100% even with plentiful angiogenesis and newborn lymphatic vessels, as well as distant metastases. As a novel approach, AdIL-12-MSC has revealed expected preventive effects on carcinogenesis (P < 0.01) with low-toxic, broad-spectrum and long-range superiorities. In conclusion, our data indicate that AdIL-12-MSC possess the potential for tropism to preclinical tumor lesions and deprives surviving or hibernating tumor cells, which have escaped from conventional treatments, of revival and recurrence.

{dagger}Both these authors contributed equally to the work.

The author names and affiliations have been altered in this version.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
M. R. Loebinger, A. Eddaoudi, D. Davies, and S. M. Janes
Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer
Cancer Res., May 15, 2009; 69(10): 4134 - 4142.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
M. R. Loebinger, E. K. Sage, and S. M. Janes
Mesenchymal Stem Cells as Vectors for Lung Disease
Proceedings of the ATS, August 15, 2008; 5(6): 711 - 716.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Eliopoulos, M. Francois, M.-N. Boivin, D. Martineau, and J. Galipeau
Neo-Organoid of Marrow Mesenchymal Stromal Cells Secreting Interleukin-12 for Breast Cancer Therapy
Cancer Res., June 15, 2008; 68(12): 4810 - 4818.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.